September 20, 2019
Merck’s Pifeltro and Delstrigo get US FDA approval for use in appropriate virologically suppressed adults living with HIV-1
USAFDA has given approvals for Merck’s Pifeltro and Delstrigo for certain HIV-1 patients, based on fFindings from the Phase 3 DRIVE-SHIFT Trial, Merck said on Friday in a press release.